<SEC-DOCUMENT>0001096906-24-000934.txt : 20240425
<SEC-HEADER>0001096906-24-000934.hdr.sgml : 20240425
<ACCEPTANCE-DATETIME>20240425145916
ACCESSION NUMBER:		0001096906-24-000934
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240425
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240425
DATE AS OF CHANGE:		20240425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		24875518

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20240425.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://utahmed.com/20240425" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VE8AL0SZ]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D240425" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D240425" id="fact2">false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20240425.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:context id="D240425">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-04-25</i:startDate>
<i:endDate>2024-04-25</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:14pt Times New Roman;margin:0;text-align:center"><b>UNITED STATES </b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center"><b>Washington, D.C. &#160;20549</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="D240425" escape="true" id="ixv-337">8-K</ix:nonNumeric></b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>CURRENT REPORT</b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;text-align:center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">Date of Report (date of earliest event reported): &#160;<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D240425" format="ixt:date-monthname-day-year-en" id="ixv-338">April 25, 2024</ix:nonNumeric></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D240425" escape="true" id="ixv-339">UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D240425" format="ixt-sec:stateprovnameen" id="ixv-340">Utah</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D240425" escape="true" id="ixv-341">000-12575</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D240425" escape="true" id="ixv-342">87-0342734</ix:nonNumeric></b></p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Commission File Number)</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(IRS Employer</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">incorporation or organization)</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Identification No.)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D240425" escape="true" id="ixv-343">7043 South 300 West</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D240425" escape="true" id="ixv-344">Midvale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D240425" format="ixt-sec:stateprovnameen" id="ixv-345">Utah</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D240425" escape="true" id="ixv-346">84047</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices)</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Zip code)</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0">Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Phone: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="D240425" escape="true" id="ixv-347">801</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D240425" escape="true" id="ixv-348">566-1200</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>n/a</b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="D240425" format="ixt-sec:boolballotbox" id="ixv-349">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="D240425" format="ixt-sec:boolballotbox" id="ixv-350">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="D240425" format="ixt-sec:boolballotbox" id="ixv-351">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="D240425" format="ixt-sec:boolballotbox" id="ixv-352">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign="top" style="width:5.86%"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:94.14%"><p style="font:10pt Times New Roman;margin:0;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D240425" format="ixt-sec:boolballotbox" id="ixv-353">&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Wingdings"><span style="font-family:Wingdings">&#168;</span></span></p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:11pt Times New Roman;margin:0"><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;margin-left:72pt">Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2024 and forward-looking statements relating to 2024 and beyond as presented in a press release dated April 25, 2024. &#160;</p>
<p style="font:11pt Times New Roman;margin:0;margin-left:72pt">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;margin-left:72pt">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style="font:11pt Times New Roman;margin:0">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0"><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">The following is filed as an exhibit to this report: &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Exhibit</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Number*</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Title of Document</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Location</b></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Item 99.1</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex99z1.htm" style="text-decoration:none">Financial information for Utah Medical Products, Inc. for the three</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> months</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> ended March 31, 2024 and forward-looking statements relating to 2024 and beyond as presented in a press release dated April 25, 2024.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">This filing</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">_______________________________________</p>
<p style="font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:-18pt">*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:11pt Times New Roman;margin:0;text-align:center"><b>SIGNATURES</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Dated:  April 25, 2024</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">By:</p>
</td><td valign="top" style="width:218.05pt;border-bottom:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:218.05pt;border-top:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0">Kevin L. Cornwell, <br/>Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE ENDED MARCH 31, 2024 AND FORWARD-LOOKING STATEMENTS RELATING TO 2024 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED APRIL 25, 2024.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VE8AL0SZ]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><B>Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024</B></P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:50%><P style='font:11pt Times New Roman;margin:0'>Contact: Brian Koopman (801) 566-1200</P>
</TD><TD valign=top style=width:50%><P align=right style='font:11pt Times New Roman;margin:0'>April 25, 2024</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;In the first calendar quarter (1Q) of 2024, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with its previously announced projections for calendar year 2024. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Summary of results</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>The following is a summary comparison of 1Q 2024 with 1Q 2023 income statement measures:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:50%><TR><TD valign=top style=background-color:#CCEEFF;width:57.4%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:42.6%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;(9.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:57.4%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:42.6%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> (13.7%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:57.4%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:42.6%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> (12.5%)</P>
</TD></TR>
<TR><TD valign=top style=width:57.4%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top style=width:42.6%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;(6.1%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:57.4%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:42.6%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;(5.7%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Profit margins in 1Q 2024 compared to 1Q 2023 follow:</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>1Q 2024 </P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(JAN &#8211;&nbsp;MAR)</FONT></P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>1Q 2023 </P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(JAN &#8211;&nbsp;MAR)</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (gross profits/ sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>59.7%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>62.6%</P>
</TD></TR>
<TR><TD valign=top style=width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (operating income/ sales):</P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>34.2%</P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>35.5%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>EBT Margin (profits before income taxes/ sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>42.3%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>40.9%</P>
</TD></TR>
<TR><TD valign=top style=width:60.66%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.25pt'>Net Income Margin (profit after taxes/ sales):</P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>34.9% </P>
</TD><TD valign=top style=width:19.68%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>33.7% </P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Domestic sales in 1Q 2024 were 14% lower and sales outside the U.S. (OUS) were 3% lower, in USD terms, compared to 1Q 2023. &nbsp;Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in &#8220;constant currency&#8221; terms, OUS sales were 4% lower. Although 31% of consolidated USD sales were invoiced in foreign currencies, the change in FX rates for OUS sales had a minor impact on period-to-period relative financial results. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1Q 2024 and 1Q 2023 follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:70%><TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'><A name=_Hlk164929877 />&nbsp;</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2024</FONT></P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2023</FONT></P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>1.267</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>1.215</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>4.3%</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>1.083</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>1.078</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.4%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.658</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.685</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>(4.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.742</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.739</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.4%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The weighted-average positive impact on foreign currency sales was 1.2%, increasing reported USD sales $40 relative to the same foreign currency sales in 1Q 2023. &nbsp;In constant currency terms, total consolidated 1Q 2024 sales were $1,220 (9.7%) lower than in 1Q 2023.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s 1Q 2024 GP at $6,766 was $1,077 lower than 1Q 2023 GP of $7,843. &nbsp;The 13.7% lower GP was the result of 9.4% lower sales combined with a Gross Profit Margin (GPM), GP/revenues, almost three percentage points lower than in 1Q 2023. The lower GPM was due to manufacturing overhead costs which did not decline proportionately to the sales decline. However, the decline in GPM was less than expected due to a favorable product mix and improved direct labor productivity. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated OI, which is GP less Operating Expense (OE), in 1Q 2024 at $3,883 (34.2% of sales) was $556 lower than 1Q 2023 OI of $4,439 (35.5% of sales). &nbsp;The OI decline was less than the GP decline as a result of the favorable impact in General &amp; Administrative (G&amp;A) expenses of having the CSI Identifiable Intangible Asset (IIA) fully amortized in 4Q 2023. &nbsp;The CSI IIA amortization expense was $1,105 in 1Q 2023 (and zero in 1Q 2024). &nbsp;Offsetting the lower CSI IIA amortization expense in G&amp;A expenses were $342 higher litigation expenses. Combining the changes in CSI IIA amortization and litigation costs with other G&amp;A expense increases, total consolidated G&amp;A expenses were just $668 lower in 1Q 2024 than in 1Q 2023. The other components of OE, Product Development (R&amp;D) expenses and Sales &amp; Marketing (S&amp;M) expenses, were $122 and $25 higher in 1Q 2024 than in 1Q 2023, respectively. &nbsp;The higher R&amp;D expense was related to certification of UTMD&#8217;s own biopharma manufacturing pressure sensors. In sum, OE were $522 lower in 1Q 2024 than in 1Q 2023.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Income Before Tax (EBT) benefitted again from higher interest income on UTMD&#8217;s cash reserves. &nbsp;&nbsp;Non-operating income (NOI) in 1Q 2024, in which interest income is captured, was $915 compared to $681 in 1Q 2023. Combining the $555 lower OI with $234 higher NOI yielded 1Q 2024 EBT just $321 (6.3%) lower than in 1Q 2023. &nbsp;In contrast to a lower GPM and OIM, UTMD&#8217;s EBT Margin (EBT/sales) improved to 42.3% in 1Q 2024 compared to 40.9% in 1Q 2023. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s consolidated income tax provision rate in 1Q 2024 was 17.6% compared to 17.7% in 1Q 2023. As a result, 1Q 2024 NI was 6.1% lower than in 1Q 2023. During 1Q 2024 UTMD repurchased 43,108 of its shares in the open market at an average cost of $69.37/ share. UTMD did not repurchase shares in 2023. Also, because of a lower stock price at the end of 1Q 2024, there was no dilution from outstanding employee stock options for purposes of calculating diluted EPS, compared to 8,456 in share dilution in 1Q 2023. Because of the benefit of lower time-weighted diluted shares, UTMD&#8217;s EPS in 1Q 2024 were 5.7% lower than in 1Q 2023.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s March 31, 2024 Balance Sheet, in the absence of debt, remained strong. &nbsp;Ending Cash and Investments were $93.8 million on March 31, 2024 compared to $92.9 million three months earlier on December 31, 2023, despite use of $4.1 million cash during 1Q 2024 to pay for stockholder dividends and share repurchases. Stockholders&#8217; Equity (SE) remained about the same at the end of 1Q 2024 as at the end of 2023, as $4.1 million in dividends and share repurchases which reduced SE offset $4.0 million in 1Q 2024 NI which increased SE. &nbsp;FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2024 and the end of 1Q 2023 follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:70%><TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3-31-24</FONT></P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3-31-23</FONT></P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>1.263</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>1.237</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>2.1%</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>1.079</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>1.087</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>(0.7%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.652</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.670</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=right style='font:11pt Times New Roman;margin:0'>(2.7%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.739</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>0.739</P>
</TD><TD valign=top style=width:25%><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 1Q 2024 UTMD sales were $1,180 (9.4%) lower than in 1Q 2023. Constant currency sales were $1,220 (9.7%) lower. U.S. domestic sales were 13.8% lower and OUS sales were 3.5% lower. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Domestic sales in 1Q 2024 were $6,192 compared to $7,185 in 1Q 2023. &nbsp;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;Filshie device sales&#8221;, manufactured by Femcare and distributed in the U.S. by UTMD. </P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Direct sales, representing 57% of total domestic sales, were $106 (2.9%) lower in 1Q 2024 than in 1Q 2023. &nbsp;This was due to $139 lower NICU device sales as a result of not yet recapturing business lost in late 2023 from continuing supply chain disruption for raw material components. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>OEM sales, representing 26% of total domestic sales, were $691 (29.9%) lower. U.S. sales to UTMD&#8217;s largest OEM customer, which had grown rapidly in previous years, were $735 lower in 1Q 2024 compared to 1Q 2023. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Domestic Filshie device sales were $197 (15.6%) lower in 1Q 2024 compared to 1Q 2023. &nbsp;Misinformation on social media from unresolved product liability lawsuits seems to be having a negative effect. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales in 1Q 2024 were $5,149 compared to $5,335 in 1Q 2023. OUS sales invoiced in GBP, EUR, AUD and CAD currencies were increased $40 as a result of changes in FX rates resulting primarily from a 4.3% stronger GBP. &nbsp;In other words, constant currency OUS sales were $5,109, which was 4.2% lower than in 1Q 2023. &nbsp;The foreign currency OUS sales in 1Q 2024 were $3,487, which was 68% of OUS sales and 31% of total 1Q 2024 consolidated sales. &nbsp;Foreign currency OUS sales in 1Q 2023 were $3,558, which was 67% of OUS sales and 28% of total 1Q 2023 consolidated sales. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the costs of manufacturing products, including quality assurance and freight for receiving raw materials from vendors, from revenues. UTMD&#8217;s GP was $1,077 (13.7%) lower in 1Q 2024 than in 1Q 2023. &nbsp;GP declined more than revenues due to lower absorption of manufacturing overhead costs which were 3.6% lower when sales were 9.4% lower. &nbsp;Because management expects revenues to decline further during the remainder of 2024, taken together with manufacturing overhead expenses not declining, management has projected a greater percentage decline in GP for the year as a whole.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. OE is comprised of G&amp;A expenses, sales and marketing (S&amp;M) expenses and product development (R&amp;D) expenses. &nbsp;Consolidated OE were $2,882 in 1Q 2024 (25.4% of sales) compared to $3,404 in 1Q 2023 (27.2% of sales). &nbsp;Ignoring the portion of OE that were litigation expenses and non-cash IIA amortization expenses, OE in 1Q 2024 were 14.4% of consolidated sales compared to 11.2% of sales in 1Q 2023. &nbsp;As noted above, the main FX rate differences in 1Q 2024 compared to 1Q 2023 were a stronger GBP and a weaker AUD relative to the USD. &nbsp;The net FX impact on OUS OE was minor. A stronger GBP in 1Q 2024 compared to 1Q 2023 increased IIA amortization expense captured in the G&amp;A category in the UK by $21. All other OUS OE were increased by $7. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated G&amp;A expenses were $2,205 (19.4% of sales) in 1Q 2024 compared to $2,873 (22.9% of sales) in 1Q 2023. G&amp;A expenses include litigation costs which were $751 in 1Q 2024 compared to $409 in 1Q 2023. G&amp;A expenses in 1Q 2024 included $504 (4.4% of sales) of non-cash expense from the amortization of IIA resulting from the 2011 Femcare acquisition, which were $483 (3.9% of sales) in 1Q 2023. The increase was the result of a stronger GBP as the Femcare GBP-denominated expense was the same in both periods. The major G&amp;A expense change was the $1,105 IIA amortization expense in 1Q 2023 which was zero in 1Q 2024. That prior expense had resulted from UTMD&#8217;s purchase in 2019 of the CSI remaining U.S. exclusive Filshie intangible and distribution rights, and represented 8.8% of 1Q 2023 sales. Excluding litigation costs and non-cash Filshie-related IIA amortization expenses, G&amp;A expenses were $950 (8.4% of sales) in 1Q 2024 compared to $876 (7.0% of sales) in 1Q 2023. The change in FX rates increased 1Q 2024 OUS G&amp;A expenses by $27, comprised of increasing IIA amortization expense by $21 and all other G&amp;A expenses by $6. &nbsp;UTMD&#8217;s OIM excluding IIA amortization and litigation expense was 45.3% in 1Q 2024 compared to 51.4% in 1Q 2023.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>S&amp;M expenses were $412 (3.6% of sales) in 1Q 2024 compared to $387 (3.1% of sales) in 1Q 2023. &nbsp;The change in FX rates increased 1Q 2024 OUS S&amp;M expenses by $1. &nbsp;The additional $24 increase was primarily due to increases in <A name=_Hlk164328705 />S&amp;M salaries and benefits for employees on board in both periods.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>R&amp;D expenses in 1Q 2024 were $266 (2.3% of sales) compared to $144 (1.1% of sales) in 1Q 2023. &nbsp;There were no OUS R&amp;D expenses. The $122 increase was primarily due to testing and certification of materials required for biopharma manufacturing OEM customers.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In summary, OI in 1Q 2024 was $3,883 (34.2% of sales) compared to $4,439 (35.5% of sales) in 1Q 2023. &nbsp;The only slightly lower 1Q 2024 OI Margin of 34.2% compared to 35.5% in 1Q 2023 was due to lower GP and higher litigation and R&amp;D expenses being offset by the expiration of CSI IIA amortization expense. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT).</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. Consolidated 1Q 2024 EBT was $4,798 (42.3% of sales) compared to $5,119 (40.9% of sales) in 1Q 2023. The $321 (6.3%) lower 1Q 2024 EBT compared to 1Q 2023 was the result of $555 lower OI offset by $234 higher NOI. NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. NOI in 1Q 2024 included $283 higher interest income on UTMD&#8217;s cash balances.</P>
<P style='font:9pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The EBT of Utah Medical Products, Inc. in the U.S. was $2,806 in 1Q 2024 compared to $2,562 in 1Q 2023. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,640 in 1Q 2024 compared to EUR 1,962 in 1Q 2023. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (101) in 1Q 2024 compared to GBP 23 in 1Q 2023. The 1Q 2024 EBT of Utah Medical Products Canada, Inc. was CAD 66 in 1Q 2024 compared to CAD 158 in 1Q 2023. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2024 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) were $5,547 compared to $6,919 in 1Q 2023. Management believes that the 1Q 2024 operating performance provides a start that is consistent with achieving its financial performance projections for the calendar year 2024, as previously provided in its Year 2023 SEC 10-K Report. UTMD&#8217;s trailing twelve-month EBITDA was $25,262.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>NI in 1Q 2024 of $3,956 was 6.1% lower than the NI of $4,214 in 1Q 2023. UTMD&#8217;s NI Margin, NI divided by consolidated sales, was 34.9% in 1Q 2024 and 33.7% in 1Q 2023. The average consolidated income tax provision rates (as a % of EBT) in 1Q 2024 was 17.6% and 17.7% in 1Q 2023. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EPS in 1Q 2024 at $1.093 were 5.7% lower than the $1.159 in 1Q 2023. &nbsp;UTMD&#8217;s smaller decline in EPS relative to NI was a result of 18,118 fewer diluted shares used to calculate EPS in 1Q 2024 compared to 1Q 2023. Diluted shares were 3,618,168 in 1Q 2024 compared to 3,636,286 in 1Q 2023. &nbsp;Outstanding shares were 3,588,336 at the end of 1Q 2024. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares for option shares exercised and for shares which were repurchased during the quarter. There was no dilution from unexercised employee options. &nbsp;The total number of outstanding unexercised employee and outside director options at March 31, 2024 was 81,995 at an average exercise price of $75.10, including shares awarded but not yet vested. This compares to 84,301 unexercised option shares at the end of 2023 at an average exercise price of $74.56/ share, including shares awarded but not vested. There were no shares added for 1Q 2024 EPS dilution from options because the average exercise price was higher than the 1Q 2024 ending share price of $71.11. &nbsp;The number of shares added as a dilution factor in 1Q 2023 was 8,456.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Outstanding shares at the end of 1Q 2024 were 3,588,336 compared to 3,629,525 at the end of calendar year 2023 and 3,628,067 at the end of 1Q 2023. The difference in outstanding shares at the end of 1Q 2024 compared to the end of 2023 resulted from 43,108 shares repurchased in the open market and 1,919 employee options exercised during 1Q 2024.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>As mentioned above, UTMD repurchased 43,108 of its shares at an average price of $69.37 during 1Q 2024. Because of a time-weighted calculation, the full antidilution impact of 1Q 2024 repurchases won&#8217;t be felt until 2Q 2024. There were no stock repurchases in 2023. No options were awarded in 1Q 2024 or 1Q 2023. During the rest of 2023 after 1Q 2023, 19,000 option shares were awarded to 48 employees at an exercise price of $77.07. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD paid $1,089 ($0.300/share) in cash dividends to stockholders in 1Q 2024. UTMD paid $1,070 ($0.295/share) in cash dividends to stockholders in 1Q 2023. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In 1Q 2024, UTMD repurchased 43,108 shares at $69.37 per share. During 1Q 2023, UTMD did not repurchase any of its shares. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 1Q 2024 was $71.11, down 16% from the $84.22 closing price at the end of 2023. &nbsp;The closing share price at the end of 1Q 2023 was $94.77. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>At March 31, 2024 compared to three months earlier at the end of 2023, UTMD&#8217;s cash and investments increased $939 to $93.8 million. Compared to a year earlier at March 31, 2023, cash and investments increased $12.9 million. At March 31, 2024, net Intangible Assets declined $611 to 13.3% of total consolidated assets from 13.8% on December 31, 2023. &nbsp;The decline in Net Intangible Assets from a year earlier was $4.4 million. &nbsp;Inventories declined $342 from the end of 2023, and $0.7 million from a year earlier. Working capital at the end of 1Q 2024 remained about the same as at the end of 2023, but was $12.6 million higher than at March 31, 2023, primarily as a result of the increase in cash. UTMD&#8217;s strong current ratio improved to 19.6 at March 31, 2024 from 15.7 at March 31, 2023. &nbsp;The current ratio at the end of 2023 was 22.6. Consolidated Accounts Receivable (net of allowances) increased $201 at March 31, 2024 from the end of 2023, but declined $0.2 million compared to March 31, 2023. &nbsp;On a rolling sales quarter basis, the aging of receivables remained at a healthy 28.5 days at the end of 1Q 2024 compared to 24.3 days at the end of 2023, and 27.3 days at the end of March 2023.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>As of March 31, 2024, Stockholders&#8217; Equity (SE) increased $9.7 million compared to a year earlier at March 31, 2023 despite a reduction in SE from the $7.3 million combination of share repurchases and ($1.19/ share) in stockholder cash dividends paid during the last twelve months. &nbsp;During 1Q 2024, SE decreased $570 from the end of 2023 while the company paid $1,089 in dividends and repurchased $2,990 in stock, which reduced SE by $4.1 million.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Financial ratios as of March 31, 2024 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 19.6&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 1Q 2024 sales activity) = 28.5&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 1Q 2024 CGS) = 1.9&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2024 YTD ROE (before dividends) = 12.4%&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:12pt Times New Roman;margin:0'><I>Utah Medical Products, Inc.</I></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>INCOME STATEMENT, First Quarter ended March 31 </P>
<P style='font:11pt Times New Roman;margin:0'>(in thousands except Earnings Per Share)</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:38.42%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:18.48%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2024</FONT></P>
</TD><TD valign=top style=width:19.26%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2023</FONT></P>
</TD><TD valign=top style=width:23.84%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:38.42%><P style='font:11pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:18.48%><P align=right style='font:11pt Times New Roman;margin:0'>$11,340</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.26%><P align=right style='font:11pt Times New Roman;margin:0'>$12,520</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:23.84%><P align=right style='font:11pt Times New Roman;margin:0'>(9.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:38.42%><P style='font:11pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:18.48%><P align=right style='font:11pt Times New Roman;margin:0'>6,766</P>
</TD><TD valign=top style=width:19.26%><P align=right style='font:11pt Times New Roman;margin:0'>7,843</P>
</TD><TD valign=top style=width:23.84%><P align=right style='font:11pt Times New Roman;margin:0'>(13.7%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:38.42%><P style='font:11pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:18.48%><P align=right style='font:11pt Times New Roman;margin:0'>3,883</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.26%><P align=right style='font:11pt Times New Roman;margin:0'>4,439</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:23.84%><P align=right style='font:11pt Times New Roman;margin:0'>(12.5%)</P>
</TD></TR>
<TR><TD valign=top style=width:38.42%><P style='font:11pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:18.48%><P align=right style='font:11pt Times New Roman;margin:0'>4,798</P>
</TD><TD valign=top style=width:19.26%><P align=right style='font:11pt Times New Roman;margin:0'>5,119</P>
</TD><TD valign=top style=width:23.84%><P align=right style='font:11pt Times New Roman;margin:0'>(6.3%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:38.42%><P style='font:11pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:18.48%><P align=right style='font:11pt Times New Roman;margin:0'>3,956</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.26%><P align=right style='font:11pt Times New Roman;margin:0'>4,214</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:23.84%><P align=right style='font:11pt Times New Roman;margin:0'>(6.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:38.42%><P style='font:11pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style=width:18.48%><P align=right style='font:11pt Times New Roman;margin:0'>$1.093</P>
</TD><TD valign=top style=width:19.26%><P align=right style='font:11pt Times New Roman;margin:0'>$1.159</P>
</TD><TD valign=top style=width:23.84%><P align=right style='font:11pt Times New Roman;margin:0'>(5.7%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:38.42%><P style='font:11pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:18.48%><P align=right style='font:11pt Times New Roman;margin:0'>3,618</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.26%><P align=right style='font:11pt Times New Roman;margin:0'>3,636</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:23.84%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:4.5pt;margin-left:-18pt'>BALANCE SHEET</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>(unaudited) &nbsp;</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2024</FONT></P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2023</FONT></P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2023</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$ 93,808</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>$ 92,868</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$ 80,912</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>3,591</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>3,391</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>3,818</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;Inventories</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>9,240</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>9,582</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>9,940</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;Other Current Assets</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>510</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>428</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>442</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>107,149</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>106,269</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>95,112</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>10,266</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>10,552</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>10,241</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>18,026</FONT></P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>18,637</FONT></P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>22,417</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$135,441</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>$135,458</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$127,770</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>998</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>769</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>1,027</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>558</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>558</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>419</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,918</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,383</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4,628 </FONT></P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'> 5,474</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;4,710</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;6,074</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangibles</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>986</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>1,120</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>1,456</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Long Term Lease Liability</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>285</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>295</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>328</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>1,256</P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'>Deferred Income Taxes</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>256</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>322</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>638</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.48%><P style='font:11pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>127,742</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>128,313</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>118,018</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:48.48%><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$135,441</P>
</TD><TD valign=top style=width:16.52%><P align=right style='font:11pt Times New Roman;margin:0'>$135,458</P>
</TD><TD valign=top style=width:17.5%><P align=right style='font:11pt Times New Roman;margin:0'>$127,770</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20240425_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VE8AL0SZ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240425"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240425.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20240425_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VE8AL0SZ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240425"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Securities Act File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20240425_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VE8AL0SZ]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20240425"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240425.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20240425.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK5GW761L0VE8AL0SZ]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://utahmed.com/20240425' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://utahmed.com/20240425' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2023'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240425_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240425_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240425_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2023/dei-2023.xsd' namespace='http://xbrl.sec.gov/dei/2023'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140300034767664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Apr. 25,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
M  @ 9W>96%==RW[M P  GPX  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6REEVMOXC@4AO^*E956NU+;7 B7=@&)TG8'32^HT*VTW]S$@#6.G;6=TO[[
M/0Z0L#/A9*3E [$3G]=/CNW7\7"K]#>S8<R2CTQ(,_(VUN97OF^2#<NHN5 Y
MD_!DI71&+53UVC>Y9C0M@S+A1T'0\S/*I3<>EO?F>CQ4A15<LKDFIL@RJC^O
MF5#;D1=ZAQO/?+VQ[H8_'N9TS1;,ON1S#36_4DEYQJ3A2A+-5B-O$EY=1V5
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M'LQ7P_0[\\:__A+V@C\0K$Z%U<'4Q\]LS8W5%#(WG7UMHL/C _CU@U[O<H#
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M,NT:P/.54O90<8>:ZDPZ_A=02P,$%     @ 9W>96)^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ 9W>96 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !G
M=YE8-=1K2/     K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !G=YE8F5R<(Q &  "<)P  $P
M@ '. 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &=WF5A77<M^
M[0,  )\.   8              " @0\(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !G=YE8GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"  "2$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20240425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20240425.htm">utmd-20240425.htm</File>
    <File>utmd-20240425.xsd</File>
    <File>utmd-20240425_def.xml</File>
    <File>utmd-20240425_lab.xml</File>
    <File>utmd-20240425_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20240425.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20240425",
   "dts": {
    "inline": {
     "local": [
      "utmd-20240425.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20240425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20240425_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20240425_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20240425_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D240425",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240425",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240425.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20240425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001096906-24-000934-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-24-000934-xbrl.zip
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M6Z_\Y[MY]RQO5S8M._5V,Y^F;TI?-J^ZDVO-O[9^:74[+_9P+R5[):[NPC:
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MC(1)+KHI42>?>MZTWQLF7?,*[4'@CA6K/C6YQJU%D*E!#0>X:G7?GU3@$L^
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MQR]WS7ICF._>?[;<C1="\P6P).H<_P902P,$%     @ 9W>96'?^+.47 @
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MM<NCGK Q("C0HJO#+W- "]$G1_\KP^IO4$L#!!0    ( &=WF5@Q G2)-P@
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M;43K6T0*?A%OQ(E]/YI!D:<;G\O+>%F[]$O)O$$5+"A+V&1"CVM_/A85@DR
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MSQ0V49,'K"]:41XFF ) 7HL40%:!%#@H,[.XOG*::& B.SOAPW]=5POH&^8
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M@-1!96K>4Z6#*6?P]<F&I.)H-RT!>!T4GG>"*(69>4Z8L/R1K>T6BUU7<="
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M<<G'J\O;LAQ1WUN3[R 8PV#(_MRD_P%^IV.8XPE1)+?W_A G^&"^X+!N\1R
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M>&IZ7F I]6Z!_;8#GJEMBI3SS0LXYNI\/L?,I.FEE*<G!GX"B7W5HXP4N''
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M_^@G),FF69[$ADHWI[+"((^24>2YTS*<IE6"O8SXV?++)2!KF:XG*Z.7 +
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M,#(T,#0R-2YX<V102P$"% ,4    " !G=YE8=_XLY1<"   F!P  %0
M        @ &K$0  =71M9"TR,#(T,#0R-5]D968N>&UL4$L! A0#%     @
M9W>96#$"=(DW"   VDX  !4              ( !]1,  '5T;60M,C R-# T
M,C5?;&%B+GAM;%!+ 0(4 Q0    ( &=WF5AK@-D$J04  $8T   5
M      "  5\<  !U=&UD+3(P,C0P-#(U7W!R92YX;6Q02P$"% ,4    " !G
M=YE8D4S<A!LC  "2S   #P              @ $[(@  =71M9%]E>#DY>C$N
9:'1M4$L%!@     &  8 A $  (-%      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>utmd-20240425_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20240425.xsd" xlink:type="simple"/>
    <context id="D240425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D240425" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D240425" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D240425" id="ixv-337">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D240425" id="ixv-338">2024-04-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D240425" id="ixv-339">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D240425" id="ixv-340">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D240425" id="ixv-341">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D240425" id="ixv-342">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D240425" id="ixv-343">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D240425" id="ixv-344">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D240425" id="ixv-345">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D240425" id="ixv-346">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D240425" id="ixv-347">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D240425" id="ixv-348">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D240425" id="ixv-349">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D240425" id="ixv-350">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D240425" id="ixv-351">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D240425" id="ixv-352">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D240425" id="ixv-353">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
